Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study

Objective To examine the degree to which use of β blockers, statins, and diuretics in patients with impaired glucose tolerance and other cardiovascular risk factors is associated with new onset diabetes. Design Reanalysis of data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Setting NAVIGATOR trial. Participants Patients who at baseline (enrolment) were treatment naïve to β blockers (n=5640), diuretics (n=6346), statins (n=6146), and calcium channel blockers (n=6294). Use of calcium channel blocker was used as a metabolically neutral control. Main outcome measures Development of new onset diabetes diagnosed by standard plasma glucose level in all participants and confirmed with glucose tolerance testing within 12 weeks after the increased glucose value was recorded. The relation between each treatment and new onset diabetes was evaluated using marginal structural models for causal inference, to account for time dependent confounding in treatment assignment. Results During the median five years of follow-up, β blockers were started in 915 (16.2%) patients, diuretics in 1316 (20.7%), statins in 1353 (22.0%), and calcium channel blockers in 1171 (18.6%). After adjusting for baseline characteristics and time varying confounders, diuretics and statins were both associated with an increased risk of new onset diabetes (hazard ratio 1.23, 95% confidence interval 1.06 to 1.44, and 1.32, 1.14 to 1.48, respectively), whereas β blockers and calcium channel blockers were not associated with new onset diabetes (1.10, 0.92 to 1.31, and 0.95, 0.79 to 1.13, respectively). Conclusions Among people with impaired glucose tolerance and other cardiovascular risk factors and with serial glucose measurements, diuretics and statins were associated with an increased risk of new onset diabetes, whereas the effect of β blockers was non-significant. Trial registration ClinicalTrials.gov NCT00097786.

[1]  M. Laakso,et al.  Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[2]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[3]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[4]  J. Avorn,et al.  Antihypertensive Drug Therapy and the Initiation of Treatment for Diabetes Mellitus , 1993, Annals of Internal Medicine.

[5]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[6]  Jackson T. Wright,et al.  Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. , 2008, Hypertension.

[7]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[8]  B. Davis,et al.  Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2006, Archives of internal medicine.

[9]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[10]  R. Califf,et al.  Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. , 2010, Cardiovascular therapeutics.

[11]  G. Curhan,et al.  Antihypertensive Medications and the Risk of Incident Type 2 Diabetes , 2006, Diabetes Care.

[12]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[13]  M. Laakso,et al.  Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[14]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[15]  W. Elliott.  Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri , 2006 .

[16]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[17]  J. Manson,et al.  Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. , 2012, Archives of internal medicine.

[18]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[19]  T. Hedner,et al.  Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Göteborg, Sweden. , 1994, Journal of human hypertension.

[20]  J. Roy,et al.  Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes , 2012, Pharmacoepidemiology and drug safety.

[21]  Paul M. Ridker,et al.  Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis , 2009, Diabetes Care.

[22]  H. Lithell,et al.  Do antihypertensive drugs precipitate diabetes in predisposed men? , 1989, BMJ.

[23]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[24]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[25]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[26]  High blood pressure and the incidence of non-insulin dependent diabetes mellitus: Findings in A 11.5 year follow-up study in the Netherlands , 1993, European Journal of Epidemiology.

[27]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[28]  ADVERSE REACTIONS TO BENDROFLUAZIDE AND PROPRANOLOL FOR THE TREATMENT OF MILD HYPERTENSION Report of Medical Research Council Working Party on Mild to Moderate Hypertension , 1981, The Lancet.

[29]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[30]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[31]  J. Robins,et al.  Method for conducting sensitivity analysis. , 1999, Biometrics.